DeepMed Research

Rogel Cancer Center: University of Michigan

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1991-01-01

Employees: -

Market Cap: -

Website: http://www.rogelcancercenter.org

Clinical Trials

Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: 68Ga-PSMA

First Posted Date: 2018-09-28

Last Posted Date: 2022-01-05

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 11

Registration Number: NCT03689582

Locations: 🇺🇸
University of Michigan Hospital, Ann Arbor, Michigan, United States

Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy

Phase 2

Active, not recruiting

Conditions: Biliary Tract Cancer

Interventions: Drug: Rucaparib
Drug: Nivolumab

First Posted Date: 2018-08-21

Last Posted Date: 2024-08-21

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 32

Registration Number: NCT03639935

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas

Phase 2

Withdrawn

Conditions: Diffuse Intrinsic Pontine Glioma
Glioma

Interventions: Drug: Panobinostat
Drug: Everolimus

First Posted Date: 2018-08-15

Last Posted Date: 2019-08-19

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT03632317

Locations: 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States

The ConnectedCancerCare Pilot Study (CCC)

Not Applicable

Completed

Conditions: Cancer Survivors
Survivorship
Early-stage Breast Cancer
Breast Cancer Female
Transitional Care

Interventions: Behavioral: Static care plan
Behavioral: CCC website

First Posted Date: 2018-08-07

Last Posted Date: 2020-11-04

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 66

Registration Number: NCT03618017

Locations: 🇺🇸
The University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Phase 2

Withdrawn

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Bortezomib
Drug: Ibrutinib

First Posted Date: 2018-08-06

Last Posted Date: 2020-06-22

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT03617484

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

Phase 1

Terminated

Conditions: Lymphoma, T-Cell, Peripheral
Chronic Lymphocytic Leukemia
Lymphoproliferative Disorders
Mantle Cell Lymphoma
Lymphoma, T-Cell, Cutaneous
Waldenstrom Macroglobulinemia
Lymphoplasmacytic Lymphoma

Interventions: Drug: Pacritinib

First Posted Date: 2018-07-26

Last Posted Date: 2021-01-22

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 4

Registration Number: NCT03601819

Locations: 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Phase 2

Completed

Conditions: Metastatic Cancer
Solid Tumor
Metastatic Castration Resistant Prostate Cancer

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2018-06-27

Last Posted Date: 2025-05-08

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 56

Registration Number: NCT03570619

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 5 locations

Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Renal Cell Carcinoma, Metastatic

Interventions: Drug: ESK981
Drug: Nivolumab

First Posted Date: 2018-06-19

Last Posted Date: 2024-05-20

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 8

Registration Number: NCT03562507

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

The Validation of a Novel Adherence Method for Oral Oncolytics

Not Applicable

Completed

Conditions: Cancer

Interventions: Other: Smart Phone Application
Other: POD

First Posted Date: 2018-06-19

Last Posted Date: 2019-10-04

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 18

Registration Number: NCT03561272

Locations: 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Stage IV Non-small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Pemetrexed
Drug: Carboplatin
Drug: Rucaparib

First Posted Date: 2018-06-15

Last Posted Date: 2025-02-26

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 25

Registration Number: NCT03559049

Locations: 🇺🇸
The University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy